Dbol 50 mg 50 Tablets Nakon Medical USA

Product Overview

Nakon Medical USA’s Dbol 50 mg presents methandienone, featuring C1,2 double bond modification conferring unique anabolic signaling with 17α-alkylation enabling oral bioavailability (~3-6 hour half-life), in round scored tablets for institutional catalog integration across DEA-registered platforms. The 50-tablet HDPE bottle configuration supports CIII-compliant inventory reconciliation under 21 CFR 1304.22 requiring detailed Schedule III accountability for institutional handlers maintaining federal/state compliance across 50 U.S. jurisdictions plus territories.​

U.S.-domiciled GMP manufacturing maintains molecular specifications (MW 300.44) distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting ±30% potency variance documented across independent analytics. This high-potency presentation serves institutional buyers requiring verified batch traceability through serialized lot numbering essential for Form 222 triplicate documentation and controlled substance workflows, eliminating grey-market authenticity uncertainty and international customs seizure exposure.

Nakon Dbol positions exclusively within verified DEA Schedule III ecosystems targeting licensed institutional clientele demonstrating controlled substance handling protocols under 21 CFR 1301.13 registrant requirements, maintaining strict commercial positioning devoid of therapeutic claims, cycle recommendations, or performance outcome representations characteristic of legitimate CIII distribution.

Brand & Manufacturer Information

Nakon Medical USA manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiring rigorous DEA registrant verification prior to encrypted fulfillment. Dbol 50 mg anchors Nakon’s high-potency methandienone catalog alongside Oxy/Tbol maintaining dosage progression (10→25→50 mg) enabling precise institutional SKU differentiation while authenticating supply chain legitimacy versus powder-pressed alternatives rejected universally by DEA-registered dispensaries.

Domestic climate-controlled warehousing supports Form 222 platforms eliminating customs risk while serialized batch documentation verifies 50 mg potency through independent HPLC assay distinguishing Nakon from non-pharmaceutical origins lacking controlled substance pedigree essential for institutional bulk procurement exceeding DEA quota allocations.​

Active Compound Information

Contains methandienone (17α-methyl-Δ¹-testosterone), first-generation anabolic steroid exhibiting C1,2 diene unsaturation conferring rapid protein synthesis stimulation, glycogenolytic activity, and nitrogen retention characteristic of testosterone derivatives with 17α-methylation preventing first-pass metabolism. DEA Schedule III classification reflects hepatotoxicity profile, estrogenic aromatization via CYP19A1 pathway, and water retention propensity supporting performance applications beyond original medical indications discontinued post-FDA reevaluation.

50 mg strength represents institutional-grade escalation from historical prescription methandienone (5-10 mg therapeutic range) while maintaining identical Δ¹ unsaturation distinguishing from standard metandienone. Molecular formula C20H28O2; logP 2.95 indicating optimal oral pharmacokinetics; WADA S1.1a prohibited globally with sensitive LC-MS/MS detection methodology.​

Product Specifications

Quality Control & Testing Standards

50 mg methandienone mandates USP <621> potency assay (HPLC 90-110%), USP <711> dissolution, USP <905> uniformity, and Δ¹-unsaturation verification confirming pharmaceutical-grade specifications. Nakon batch documentation verifies C20H28O2 identity distinguishing legitimate GMP production from underground conversions.

50-tablet CIII configuration incorporates USP <671> barriers preventing oxidative degradation while child-resistant closure satisfies 21 CFR 310.310(a). Domestic stability maintains ICH Q1A(R2) 36-month shelf-life exceeding underground alternatives.

Intended Use & Market Positioning

Dbol 50 mg serves DEA-registered CIII institutional researchers managing high-potency Schedule III anabolic inventories exclusively through encrypted fulfillment requiring Form 222 accountability. Prescription-equivalent positioning serves verified institutional clientele.

Zero protocols, cycles, or outcomes represented maintaining commercial CIII positioning.

Legal & Regulatory Disclaimer

Methandienone constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties). Institutional buyers assume Form 222/DEA licensing liability; no medical claims provided.​